These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 1500200)

  • 21. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.
    Levine MM; Kaper JB; Herrington D; Ketley J; Losonsky G; Tacket CO; Tall B; Cryz S
    Lancet; 1988 Aug; 2(8609):467-70. PubMed ID: 2900401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults.
    Migasena S; Pitisuttitham P; Prayurahong B; Suntharasamai P; Supanaranond W; Desakorn V; Vongsthongsri U; Tall B; Ketley J; Losonsky G
    Infect Immun; 1989 Nov; 57(11):3261-4. PubMed ID: 2807523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection.
    Losonsky GA; Tacket CO; Wasserman SS; Kaper JB; Levine MM
    Infect Immun; 1993 Feb; 61(2):729-33. PubMed ID: 8423098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.
    Mayo-Smith LM; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Calderwood SB; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27847368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection.
    Haney DJ; Lock MD; Gurwith M; Simon JK; Ishioka G; Cohen MB; Kirkpatrick BD; Lyon CE; Chen WH; Sztein MB; Levine MM; Harris JB
    Vaccine; 2018 May; 36(20):2768-2773. PubMed ID: 29655627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels.
    Gotuzzo E; Butron B; Seas C; Penny M; Ruiz R; Losonsky G; Lanata CF; Wasserman SS; Salazar E; Kaper JB
    Infect Immun; 1993 Sep; 61(9):3994-7. PubMed ID: 8359923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45.
    McCarty JM; Lock MD; Hunt KM; Simon JK; Gurwith M
    Vaccine; 2018 Feb; 36(6):833-840. PubMed ID: 29317118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O.
    Lagos R; Avendaño A; Prado V; Horwitz I; Wasserman S; Losonsky G; Cryz S; Kaper JB; Levine MM
    Infect Immun; 1995 Feb; 63(2):707-9. PubMed ID: 7822046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR.
    Viret JF; Dietrich G; Favre D
    Vaccine; 2004 Jun; 22(19):2457-69. PubMed ID: 15193410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae.
    Chen WH; Garza J; Choquette M; Hawkins J; Hoeper A; Bernstein DI; Cohen MB
    Clin Vaccine Immunol; 2015 Jan; 22(1):129-35. PubMed ID: 25410205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children and Adolescents Aged 6-17 Years.
    McCarty JM; Gierman EC; Bedell L; Lock MD; Bennett S
    Am J Trop Med Hyg; 2020 Jan; 102(1):48-57. PubMed ID: 31769402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae.
    Tacket CO; Losonsky G; Nataro JP; Cryz SJ; Edelman R; Fasano A; Michalski J; Kaper JB; Levine MM
    J Infect Dis; 1993 Dec; 168(6):1536-40. PubMed ID: 8245542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J; Gibson JA; Pickering BS; Watnick PI
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial.
    Kotloff KL; Wasserman SS; O'Donnell S; Losonsky GA; Cryz SJ; Levine MM
    Infect Immun; 1992 Oct; 60(10):4430-2. PubMed ID: 1398956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines.
    Kollaritsch H; Furer E; Herzog C; Wiedermann G; Que JU; Cryz SJ
    Infect Immun; 1996 Apr; 64(4):1454-7. PubMed ID: 8606118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR.
    Tacket CO; Losonsky G; Nataro JP; Cryz SJ; Edelman R; Kaper JB; Levine MM
    J Infect Dis; 1992 Oct; 166(4):837-41. PubMed ID: 1527420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge.
    Tacket CO; Losonsky G; Nataro JP; Comstock L; Michalski J; Edelman R; Kaper JB; Levine MM
    J Infect Dis; 1995 Sep; 172(3):883-6. PubMed ID: 7658089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vibrio cholerae CVD103-HgR live oral attenuated vaccine: construction, safety, immunogenicity, excretion and non-target effects.
    Cryz SJ; Kaper J; Tacket C; Nataro J; Levine MM
    Dev Biol Stand; 1995; 84():237-44. PubMed ID: 7796960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.